The stabilizing effects of staphylococcal nuclease (Nuc) and of a synthetic propeptide (LEISSTCDA, hereafter called LEISS) on the production of a model food allergen, bovine ß-lactoglobulin (BLG), in Lactococcus lactis were investigated. The fusion of Nuc to BLG (Nuc-BLG) results in higher production and secretion of the hybrid protein.
Introduction
Cow's milk allergy represents an important health problem worldwide, affecting 2 to 3% of all infants in the first two years of life (1) . Bovine ß-lactoglobulin (BLG) is the most abundant whey protein of cow's milk, and is regarded as a dominant allergen. BLG is a 162-amino acid globular protein, which contains two intramolecular disulfide bonds. We are interested in the production of BLG by recombinant bacteria to study the immunoproperties of this allergen and to evaluate the effect of administration of these bacteria on the modulation of the immune response in a murine model (2) (3) (4) . Production of BLG by Escherichia coli results essentially in a denatured form of the protein (3) . Obtaining a recombinant BLG is of great interest for the study of the relationship between the structure and the immunoreactivity of a major allergen. Moreover, expression of this allergen in non-pathogenic bacteria could be of interest for the immunomodulation of allergic reactions. BLG production in the lactic acid bacterium Lactococcus lactis (a foodgrade bacterium widely used in the food industry) results in 2 mg/l recombinant pro-S. Nouaille et al. tein (10-to 100-fold less than the BLG production obtained in E. coli (3) . In these two bacteria, recombinant BLG is mostly produced in an intracellular and denatured form (2) . Moreover, a major epitope of BLG (peptide 41-60) was successfully produced in L. lactis as a fusion protein with the staphylococcal nuclease (Nuc): 32.5 mg/l BLG hybrid protein was then obtained (4) . We now intend to improve the production and secretion of BLG by recombinant lactococci for easy recovery of high quantities of BLG from the supernatant. Moreover, the use of high-producing strains for the delivery of BLG in the gastrointestinal tract in quantities allowing the induction of a specific immune response is also a challenging possibility.
The fusion to a carrier protein (Nuc) and/ or to a synthetic propeptide, LEISSTCDA (hereafter referred to as LEISS), was repeatedly shown to stabilize and improve the production and secretion of heterologous proteins in L. lactis (5-9) when using the Nisin-Controlled Expression (NICE) (10, 11) system.
In the present study, we evaluated whether these tools can stabilize and improve the production and secretion of BLG by L. lactis. Our results show that the highest production was obtained with LEISS-Nuc-BLG. The fusions described in this study allow the improved production of BLG, a protein of considerable interest. This study also generates new perspectives for heterologous production of proteins poorly produced and secreted by L. lactis.
Material and Methods

Bacterial strains, plasmids, and media
The bacterial strains and plasmids used in this study are listed in Table 1 . L. lactis The genotypic and phenotypic characteristics are given for the strains. For the plasmids, the plasmid and cloned-cassette characteristics are given.
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was grown in M17 medium (Difco-BD, Franklin Lakes, NJ, USA) supplemented with 0.5% (w/v) glucose at 30ºC without shaking. E. coli was grown in LB (14) at 37ºC. Unless otherwise indicated, plasmid constructions were first established in E. coli TG1 and then transferred to L. lactis by electrotransformation as described (15) . Plasmids were selected by the addition of antibiotics as follows: ampicillin (100 µg/ml) and chloramphenicol (10 µg/ml) for E. coli and chloramphenicol (10 µg/ml) for L. lactis.
DNA manipulations and conditions for nisin induction
The general procedures for DNA isolations and manipulations were essentially performed as previously described (14) . Enzymes were used as recommended by the suppliers. PCR was performed using the Expand High Fidelity PCR System (Roche, Mannheim, Germany) and a Perkin Elmer Cetus apparatus (Norwalk, CO, USA). DNA sequencing was performed using a DYEnamic ET sequencing kit (Amersham, Biosciences, Piscataway, NJ, USA). For nisin promoter induction, strains were grown up to absorbance at 600 nm = 0.4-0.6 and induced with 1 ng nisin/ml for 4 h (Sigma, St. Louis, MO, USA).
Lactococcus lactis protein extraction and immunoblotting
The supernatant and cell lysate fraction were prepared from induced recombinant L. lactis as described (2) . SSD-PAGE and immunoblotting analysis with anti-Nuc or anti-BLG antibodies were performed as described (2, 4) .
Fusion of Nuc carrier protein to BLG
To test the stabilizing effect of a Nuc fusion to BLG protein, a nuc cassette harboring an NsiI restriction site at both extremities was purified from NsiI-cut pBS:NsiI:nuc (Table 1) and cloned into NsiI-cut pSEC:BLG backbones. The resulting plasmid pSEC:Nuc-BLG (Figure 1 ) was then transferred to L. lactis NZ9000.
Fusion of synthetic propeptide LEISS to BLG and Nuc-BLG hybrid protein
To improve the secretion efficiency of BLG protein and Nuc-BLG hybrid protein, a DNA fragment encoding the synthetic propeptide LEISS was fused between the signal peptide and either BLG protein or Nuc-BLG hybrid protein (Figure 1 ). For this, we first constructed a pSEC:LEISS-Nuc plasmid, previously used by Ribeiro et al. (8) . Briefly, a leiss:nuc cassette was purified from a PstIEcoRI-cut pUNuc3 plasmid (17) and cloned into a pSEC backbone purified from a PstIEcoRI-cut pSEC:Nuc (18) . To generate pSEC:LEISS:BLG and pSEC:LEISS:Nuc-BLG a blg or nuc-blg cassette was purified from an NsiI/EcoRI-cut pSEC:BLG or pSEC:Nuc-BLG plasmid, respectively, and cloned into an NsiI/EcoRI-cut pSEC:LEISS. The resulting plasmids were then introduced into L. lactis NZ9000.
Two-site enzyme immunometric assay for BLG in native (BLGn) and denatured (BLGd) conformation
The two-site enzyme immunometric assays (EIA) for BLGn and BLGd were performed in 96-well microtiter plates (Maxisorp; Nunc, Roskilde, Denmark) essentially as described (2, 19) . Briefly, microtiter plates were coated with a first monoclonal antibody (mAb, capture antibody) specific for BLG or BLGd. Then, 50 µl of standard (BLGn or BLGd) or sample at appropriate dilution and 50 µl of tracer (second mAb labeled with acetylcholinesterase) were added. After 18 h of incubation at 4ºC, the plates were extensively washed, and solidphase-bound acetylcholinesterase activity was measured by the method of Ellman (20) .
Results and Discussion
BLG production is significantly enhanced by fusion to Nuc in Lactococccus lactis
To determine the stabilizing effect of Nuc on the production of BLG in L. lactis, a recombinant L. lactis strain NZ9000 (pSEC: Nuc-BLG) was constructed. Western blot experiments using anti-BLG antibodies were then performed on protein extracts of cell and supernatant fractions of induced cultures of NZ9000 (pSEC:BLG) and NZ9000 (pSEC:Nuc-BLG) L. lactis strains to compare and analyze the production and the distribution of BLG and Nuc-BLG ( Figure  2 ). As previously observed, these experiments revealed in the cell fraction of NZ9000 (pSEC:BLG) a single band corresponding to the precursor form (preBLG, ~21 kDa) whereas no band was detected in the corresponding supernatant fraction, suggesting a weak processing and secretion of the precursor form (2) (Figure 2 ). This phenomenon has been previously observed for BLG. Western blot analysis of the cell fraction of the NZ9000 (pSEC:Nuc-BLG) strain revealed a protein which migrated at the expected size of the Nuc-BLG hybrid protein (~55 kDa); however, as observed for NZ9000 (pSEC: BLG), no proteins were detected in the supernatant (Figure 2 ). The same profile was obtained with anti-Nuc antibodies (data not shown). Thus, in order to demonstrate that L. lactis indeed secreted Nuc-BLG fusion, supernatant and cell lysate fractions of NZ9000 (pSEC:Nuc-BLG) were analyzed by a more accurate and sensitive test, the two-site EIA, that allows the determination of the quantity of BLG (2) (Figure 3) . EIA specific for BLGn and BLGd was performed on each sample and the results are reported as ng of BLGn + BLGd. The data show that Nuc-BLG is indeed secreted into the culture medium but at very low concentration (~35 ng/ ml; Figure 3B ), corresponding to ~2.5% secretion efficiency (the proportion of total 
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protein present in mature secreted form). Total production of Nuc-BLG reached ~3.5 µg/ml ( Figure 3A) . When compared to NZ9000 (pSEC:BLG), these results show that fusion of Nuc to the N-terminal part of the mature BLG moiety can improve the secretion of the recombinant protein (from 25 to ~50 ng/ml; Figure 3B ). Moreover, total BLG production in L. lactis was significantly enhanced from 1500 to ~3500 ng/ml (Figure 3A) , whereas the secretion was only slightly improved, ~50 vs ~25 ng/ml ( Figure  3B ). The BLGn/BLGd ratio was ~10% in culture medium but less than 1% in terms of total production. These values are the same as those previously reported by our group (3), showing that the presence of a highly stable and secreted protein, Nuc, does not improve the folding of BLG.
LEISS dramatically improves secretion efficiency and yield of BLG in Lactococcus lactis
In previous studies, we demonstrated that the synthetic propeptide LEISS acts as a heterologous protein secretion-enhancer in L. lactis (5) (6) (7) (8) . Here, in an attempt to improve the secretion of BLG in L. lactis, we fused the propeptide LEISS between the signal peptide of the usp45 gene (SP) and the mature moiety of the BLG protein (LEISS-BLG). This fusion is encoded by an expression cassette carried by the plasmid pSEC: LEISS-BLG (Figure 1 ). Once this plasmid was established into L. lactis (NZ9000 (pSEC:LEISS-BLG)), protein secretion was evaluated and compared with the NZ9000 (pSEC:BLG) and NZ9000 (pSEC:Nuc-BLG) strains by immunoblotting ( Figure 2 ) and two-site EIA ( Figure 3 ). As observed in Figure 2 , Western blot analysis with anti-BLG mAb revealed a single band in the cell fraction, which corresponded to the precursor form preLEISS-BLG (~25 kDa). No BLG signal was detected in the NZ9000 (pSEC: BLG) or NZ9000 (pSEC:Nuc-BLG) strain supernatant by Western blot analysis. However, two-site EIA experiments showed a dramatic improvement of BLG secretion, with BLG concentrations in the supernatant reaching values close to ~250 ng/ml ( Figure  3B ), which correspond to ~6.5% secretion efficiency. Total protein production was calculated to be ~4 µg/ml ( Figure 3A) . As was the case for Nuc-BLG, no improvement of the BLGn/BLGd ratio was observed. BLG is almost exclusively found in a denatured conformation.
Finally, we analyzed the effect of the fusion of LEISS between the SP and mature moiety of the Nuc-BLG hybrid protein (LEISS:Nuc-BLG), encoded by the plasmid pSEC:LEISS:Nuc-BLG (Figure 1 ). In this case, two-site EIA ( Figure 3 ) and Western blot (data not shown) experiments showed that secretion efficiency decreased: only ~1% of the hybrid protein was detected in the supernatant fraction vs ~1.5% observed for the NZ9000 (pSEC:Nuc-BLG) strain (Figure 3B) . Interestingly, the highest yield of BLG protein (~8 ng/ml, 2-fold higher than for LEISS-BLG alone) was obtained with this new fusion (LEISS-Nuc-BLG; Figure  3A) .
We conclude that the use of L. lactis to produce and deliver BLG (a food allergen) to the gastrointestinal tract is a good poten- tial strategy to modulate the immune response against cow's milk allergy. We previously reported BLG production and secretion in L. lactis but the yields of recombinant BLG recovered in supernatant samples were very low (2) . However, we have previously shown that low production and secretion efficiency of the oncoprotein E7 from human papillomavirus (6,7) and the Brucella abortus antigen L7/L12 (8) in L. lactis could be enhanced by the fusion of Nuc protein and/or LEISS propeptide. Here, we found that fusion of Nuc to BLG acts in a way similar to that observed with these other two proteins and also with the VP2 protein from infectious bursal disease virus (9) . Moreover, the addition of two negative charges at positions +2 and +8 of BLG by fusion of LEISS propeptide indeed improved the secretion efficiency (1.5 vs 6.5%). In conclusion, we observed that the fusion of Nuc and LEISS significantly improves both BLG production and secretion, but not the BLGn/ BLGd ratio, reaching the highest yield with the LEISS-Nuc-BLG form ( Figure 3A ) and the highest secretion with the LEISS-BLG form ( Figure 3A ). These new strains have been used to modulate the immune response against BLG in a murine model via delivery at the mucosal level (Adel-Patient K, unpublished results). These results confirm the potential use of recombinant lactococci to treat BLG allergy. Finally, L. lactis expressing BLG could be ultimately used to easily recover large quantities of BLG from culture supernatants.
